Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4333-4339

  Yang, Weilian ^a   Barth, Rolf F ^a   Adams, Dianne M ^a   Soloway, Albert H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; AUTORADIOGRAPHY; BRAIN TUMOR; CANCER GRADING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; ENERGY TRANSFER; GENE AMPLIFICATION; GENETIC TRANSDUCTION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BORON; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; EPIDERMAL GROWTH FACTOR; GLIOMA; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; ISOTOPES; NEOPLASM PROTEINS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0030799914     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Barth, R. F., Soloway, A. H., and Brugger, R. M. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer Invest., 14: 534-550, 1996.
2. Mishima, Y. (ed.). Cancer Neutron Capture Therapy. New York: Plenum Publishing Corp., 1996.
3. Soloway, A. H., and Barth, R. F. (eds.). Boron neutron capture therapy of brain tumors: current status and future prospects. J. Neuro-Oncol., 33: 1-188, 1997.
4. Barth, R. F., Yang, W., Rotaru, J. H., Moeschberger, M. L., Joel, D. D., Nawrocky, M. M., Goodman, J. H., and Soloway, A. H. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res., 57: 1129-1136, 1997.
5. Barth, R. F., Adams, D. M., Soloway, A. H., Alam, F., and Darby, M. V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem., 5: 58-66, 1994.
6. Liu, L., Barth, R. H., Adams, D. M., Soloway, A. H., and Reisfeld, R. A. Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res., 16: 2581-2588, 1996.
7. 10B to malignant gliomas. In: A. H. Soloway, R. F. Barth, and D. E. Carpenter (eds.), Advances in Neutron Capture Therapy, pp. 371-375. New York: Plenum Publishing Corp., 1993.
8. Schwechheimer, K., Huang, S., and Cavenee, W. K. EGFR gene amplification-rearrangement in human glioblastoma. Int. J. Cancer, 62: 145-148, 1995.
9. Bigner, S. H., Humphrey, P. A., Wong, A. J., Vogelstein, B., Mark, J., Friedman, H. S., and Bigner, D. D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res., 50: 8017-8022, 1990.
10. Tuzi, N. L., Venter, D. J., Kumar, S., Staddon, S. L., Lemoine, N. R., and Gullick, W. J. Expression of growth factor receptors in human brain tumors. Br. J. Cancer, 63: 227-233, 1991.
11. Diedrich, U., Lucius, J., Baron, E., Behnke, J., Pabst, B., and Zoll, B. Distribution of epidermal growth factor receptor gene amplification in brain tumors and correlation to prognosis. J. Neurol., 242: 683-688, 1995.
12. Modjtahedi, H., and Dean, C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int. J. Oncol., 4: 227-296, 1994.
13. Mendelsohn, J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog. Allergy, 45: 147-160, 1988.
14. Kalofonos, H. P., Pawlikowska, T. R., Hemingway, A., Courtenay-Luck, N., Dhokia, B., Snook, D., Sivolapenko, G. B., Hooker, G. R., Mckenzie, C. G., Lavender, P. J., Thomas, D. G. T., and Epenetos, A. A. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med., 30: 1636-1645, 1989.
15. Brady, L. W., Myamoto, C., Woo, D. V., Rackover, M., Emirich, J., Bender, H., Dadparvar. S. Steplewski Z., Koprowski, H., Black, P. Lazzaro, B., Nair, S., McCormack, T., Nieves, J., Morabito, M., and Eshleman, J. Malignant astrogliomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys., 22: 225-230, 1992.
16. Faillot, T., Magdelenat., H., Mady, E., Stasiecki, P., Fohann, D., Gropp, P., Poisson, M., and Delttre, J. Y. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery, 39: 478-483, 1996.
17. Capala, J., Barth, R. F., Bendayan, M., Lauzon, M., Adams, D. M., Soloway, A. H., Fenstermaker, R. A., and Carlsson, J. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjugate Chem., 7: 7-15, 1996.
18. Carlsson, J., Gedda, L., Grönvik, C., Hartman, T., Lindström, A., Lindström, P., Lundqvist, H., Lövqvist, A., Malmqvist. J., Olsson, P., Essand, M., Pontèn, J., Sjöberg, S., and Westermark, B. Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int. J. Radiat. Oncol. Biol. Phys., 30: 105-115, 1994.
19. Gedda, L., Olsson, P., Pontèn, J., and Carlsson, J. Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Bioconjugate Chem., 7: 584-591, 1996.
20. 99mTc and in vivo localization following intracerebral injection into normal and glioma bearing rats. Bioconjugate Chem., 8: 289-295, 1997.
21. Fenstermaker, R. A., Capala, J., Barth, R. F., Hujer, A., Kung, H. J., and Kaetzel, D. M., Jr. The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. Leukemia (Baltimore), 9 (Suppl. 1): s106-s112, 1995.
22. Barth, R. F., Adams, D. M., Soloway, A. H., Mechetner, E. B., Alam, F., and Anisuzzaman, A. K. M. Determination of boron in tissues and cells using directcurrent plasma atomic emission spectroscopy. Anal. Chem., 63: 890-893, 1991.
23. Muetterties, E. L., and Knoth, W. H. Polyhedral boranes, pp. 108-110. New York: Marcel Dekker, Inc., 1968.
24. Yang, W., Barth, R. F., Carpenter, D. E., Moeschberger, M. L., and Goodman, J. H. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery, 38: 985-992, 1996.
25. 131I-labeled epidermal growth factor in the pig visualized by dynamic scintigraphy. J. Endocrinol., 144: 5-12, 1995.
26. Moshakis, V., McIlhinney, R. A. J., and Neville, A. M. Cellular 'distribution of monoclonal antibody in human tumor after i.v. administration. Br. J. Cancer, 44: 663-669, 1981.
27. Epenetos, A. A., Snook, D., Durbin, H., Johnson, P. M., and Taylor-Papadimitrious, J. Limitation of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res., 46: 3183-3191, 1986.
28. Rowlinson, G., Snook, D., Busza, A., and Epenetos, A. A. Antibody-guided localization of intraperitoneal tumor following intraperitoneal or intravenous antibody administration. Cancer Res., 47: 6528-6531, 1987.
29. 131I labeled anti-tenascin monoclonal antibody 81C6 in patients with glioma and other intracranial malignancies. Cancer Res., 49: 2807-2831, 1989.
30. Neuwelt, E. A., Barnett, P. A., and Dahlborg, S. A. Chemotherapy and monoclonal antibody delivery to malignant brain tumors: the role of blood-brain barrier modification. In: B. B. Johansson, C. Owman, and H. Widner (eds.), Pathophysiology of the Blood-Brain Barrier, pp. 187-196. Amsterdam: Elsevier Science Publishers, 1990.
31. Phillips, P. C., Levow, C., Catterall, M., Colvin, O. M., Pastan, I., and Brem, H. Transforming growth factor-α Pseudomonas exotoxin fusion protein (TGF-α-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res., 54: 1008-1015, 1994.
32. Kassis, A. I., Adelstein, S. J., and Mariani, G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Quart. J. Nucl. Med., 40: 301-319, 1996.
33. Power, S. K., Cush, S. S., Walstad, D. L., and Kwock, L. Stereotactic intratumoral photodynamic therapy for recurrent malignant brain tumors. Neurosurgery, 29: 688-696, 1991.
34. Sneed, P. K., Lamborn, K. R., Larson, D. A., Prados, M. D., Malec, M. K., McDermott, M. W., Weaver, K. A., Phillips, T. L., Wara, W. M., and Gutin, P. H. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 35: 37-44, 1996.
35. Tamargo, R. J., Langer, R., and Brem, H. Interstitial drug delivery to the central nervous system using controlled release polymers: chemotherapy for brain tumors. Methods Neurosci., 21: 135-149, 1994.
36. Bakhshi, S., and North, R. B. Implantable pumps for drug delivery to the brain. J. Neuro-Oncol., 26: 133-139, 1995.
37. Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA. 91: 2076-2080, 1994.
38. Greig, N. H. Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: E. A. Neuwelt (ed.), Implication of the Blood-Brain Barrier and Its Manipulation, pp. 311-357. New York: Plenum Publishing Corp., 1994.
39. Tamargo, R. J., and Brem, H. Drug delivery to the central nervous system: a review. Neurosurg. Quart., 2: 259-279, 1992.
40. Loeffler, J. S., Alexander, E., III, Hochberg, F. H., Wen, P. Y., Morris, J. H., Schoene, W. C., Siddon, R. L., Morse, R. H., and Black, P. M. Clinical pattern of failure following stereotactic interstitial irradiation for malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys., 19: 1455-1462, 1990.
41. Hochberg, F. H., and Pruitt, A. Assumptions in the radiotherapy of glioblastoma. Neurology, 30: 907-911, 1980.
42. Laperriere, N. J. Critical appraisal of experimental radiation modalities for malignant astrocytomas. Can. J. Neurol. Sci., 17: 199-208, 1990.
43. Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., and Brem, H. Intratumoral chemotherapy. Neurosurgery, 37: 1129-1145, 1995.
44. Buahin, K. G., and Brem, H. Interstitial chemotherapy of experimental brain tumor: a comparison of intratumoral injection versus polymeric controlled release. J. Neuro-Oncol., 26: 103-110, 1995.
45. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S. C. Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 345: 1008-1012, 1995.
46. 2: a preliminary report. J. Neuro-Oncol., 24: 109-122, 1995.
47. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res., 2: 963-972, 1996.
48. Riva, P., Arista, A., Tison, V., Sturiale, C., Franceschi, G., Spinelli, A., Riva, N., Casi, M., Moscatelli, G., and Frattarelli, M. Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors. Cancer (Phila.), 73: 1076-1082, 1994.
49. Hartman, T., and Carlsson, J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother. Oncol., 31: 61-75, 1994.
50. Kroll, R. A., Pagel, M. A., Muldoon, L. L., Roman-Goldstein, S., and Neuwelt, E. A. Increasing volume of distribution to brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery, 38: 746-754, 1996.
51. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield. E. H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg., 82: 1021-1029, 1995.
52. Barth, R. F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas J. Neuro-Oncol., 36: in press, 1998.
53. Trojan, J., Johnson, T. R., Ilan, J., Tykociniski, M. L., and Ilan, J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin like growth factor I RNA. Science (Washington DC), 259: 94-97, 1993.
54. Tzeng, J. J., Barth, R. F., Orosz, C. G., and James, S. M. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res., 51: 2373-2378, 1991.
55. Yang, W., Barth, R. F., Rotaru, J. H., Moeschberger, M. L., Joel, D. D., Nawrocky, M. M., and Goodman, J. H. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J. Neuro-Oncol., 33: 59-70, 1997.
56. Yang, W., Barth, R. F., Rotaru, J. H., Moeschberger, M. L., Joel, D. D., Nawrocky, M. M., Goodman, J. H., and Soloway, A. H. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int. J. Radiat. Oncol. Biol., Phys., 37: 663-672, 1997.